RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma.
Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
切除后复发仍然是肝细胞癌(HCC)治疗中一个难以解决的问题。自然杀伤(NK)细胞输注被认为是一种有前景的癌症疗法,但酸性肿瘤微环境(TME)和中性粒细胞胞外诱捕网(NETs)极大地削弱了其疗效。近年来,聚合物水凝胶在肿瘤联合治疗中引起了广泛关注,因为它们能够以高生物利用度和低全身毒性负载并可控释放治疗药物。
因此,一种具有肿瘤酸性中和剂和NETs裂解酶功能的生物相容性水凝胶,可能有望增强NK细胞输注以预防切除后HCC复发。在此,开发了一种双重pH响应水凝胶,其负载肿瘤酸性中和剂(介孔生物活性玻璃纳米颗粒)和NETs裂解酶(脱氧核糖核酸酶I,DNase I),并将其与NK细胞输注联合用于预防切除后HCC复发。该水凝胶可注射至手术切缘并形成黏附性凝胶,具有快速止血作用。
此外,它可中和肿瘤酸性以减少免疫抑制细胞的肿瘤浸润,并以pH响应方式释放DNase I以降解NETs。而且,这种联合治疗显著增强了NK细胞输注对抗术后HCC复发的能力,且无全身毒性。
本研究提供了概念验证,即NK细胞过继治疗与水凝胶递送系统的联合能够成功预防切除后HCC复发。
Post-resection recurrence remains an intractable problem in hepatocellular carcinoma (HCC) management. Natural killer (NK) cell infusion is considered as a promising cancer therapy, but acidic tumor microenvironment (TME) and neutrophil extracellular traps (NETs) greatly counteract its efficacy. Recently, polymer hydrogels have aroused much interest in tumor combination therapy, since they load and controllably release therapeutic agents with high bioavailability and low systemic toxicity.
Therefore, a biocompatible hydrogel with tumor acidity neutralizer and NETs lyase may show promise for enhancing NK infusion to prevent post-resection HCC recurrence.
Herein, a dual pH-responsive hydrogel with tumor acidity neutralizer (mesoporous bioactive glass nanoparticles) and NETs lyase (Deoxyribonuclease I, DNase I) is developed and used in combination with NK cell infusion for preventing post-resection HCC recurrence. The hydrogel can be injected to surgical margin and form an adhesive gel with a rapid hemostasis. Besides, it neutralizes tumor acidity to reduce tumor infiltration of immunosuppressive cells, and releases DNase I in a pH-responsive manner to degrade NETs.
Moreover, this combination therapy significantly enhances NK cell infusion to combat post-surgical HCC recurrence without systemic toxicity.
This study provides proof of concept that combination of NK cell adoptive therapy and hydrogel-based delivery system can successfully prevent post-resection HCC recurrence.
MEMBER ACCOUNT
登录成功会直接打开下一页。